Therapeutic HPV16 E7 Vaccination with CD137 Agonism Induces Tumour Regression and Durable Immunity in Mice

ABSTRACT: Therapeutic HPV16 E7 vaccination was evaluated in the syngeneic TC-1 tumour model in female C57BL/6 mice. Bulk RNA sequencing was performed on pooled, non-adherent mononuclear cell-enriched fractions prepared from subcutaneous tumour samples. The dataset compares PBS or vehicle controls, MPLA-adjuvanted wild-type E7 vaccination, MPLA-adjuvanted recombinant overlapping peptide E7 (ROP-E7) vaccination, anti-CD137 (4-1BB) agonism, and ROP-E7 plus anti-CD137 combination therapy. The study was designed to characterise treatment-associated changes in tumour immune and stromal transcriptional signatures.

ORGANISM(S): Mus musculus

PROVIDER: GSE347031 | GEO | 2026/09/25

REPOSITORIES: GEO